Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Estropipate
Drug ID BADD_D00836
Description Estrone sulfate (as estropipate) is a form of estrogen. It has several uses such as: alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics, treatment of vaginal atrophy, treatment of some types of breast cancer (particularly in men and postmenopausal women), treatment of prostate cancer and prevention of osteoporosis.
Indications and Usage Estropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause, and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. It is also used to treat hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevent postmenopausal osteoporosis.
Marketing Status Prescription; Discontinued
ATC Code G03CA07; G03CC04
DrugBank ID DB04574
KEGG ID D00948
MeSH ID C009927
PubChem ID 5284555
TTD Drug ID D03IUY
NDC Product Code 64918-0106; 12875-9998
Synonyms estropipate | piperazine estrone sulfate | estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, compd. with piperazine (1:1) | Ogen | Harmogen | Genoral | Harmonet | Ortho-Est
Chemical Information
Molecular Formula C22H32N2O5S
CAS Registry Number 7280-37-7
SMILES CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O.C1CNCCN1
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dysmenorrhoea21.01.01.002--
Dyspareunia21.03.02.016; 19.08.05.004--
Dysuria20.02.02.002--
Ectropion of cervix21.06.01.004--Not Available
Embolism venous24.01.01.003--Not Available
Endometrial cancer21.07.02.002; 16.12.02.001--Not Available
Endometrial hyperplasia21.07.01.002--Not Available
Endometriosis21.07.01.004--Not Available
Epilepsy17.12.03.002--Not Available
Erythema23.03.06.001--Not Available
Erythema multiforme10.01.03.015; 23.03.01.003--
Erythema nodosum23.07.02.001; 10.02.01.020--Not Available
Fibrocystic breast disease21.05.01.002; 16.14.01.003--Not Available
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Galactorrhoea21.05.02.002; 05.03.04.002--Not Available
Gallbladder disorder09.03.02.001--Not Available
Glucose tolerance decreased13.02.02.004--Not Available
Haemangioma24.03.06.004; 16.02.01.002--Not Available
Haemangioma of liver16.06.01.003; 09.04.01.003; 24.03.06.006--Not Available
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
Hirsutism23.02.04.001; 05.05.01.005--
Hypercalcaemia14.04.01.003; 05.04.01.002--
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hypernatraemia14.05.04.001--
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages